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Chronic venous disease (CVD) has a range of clinical presentations, including tortuous, distended veins in lower
extremities, increasing skin pigmentation, and in severe cases ulceration of the affected skin. Venous insufficiency,
a precursor to CVD characterized by improper return of blood from the lower extremities to the heart, must be
studied in its earliest stages at a time when preventative measures could be applied in man. This underscores the
need for basic research into biomarkers and genetic predisposing factors affecting the progression of venous
disease. Investigation over the past decade has yielded insight into these specific genetic, cellular and molecular
mechanisms underlying the development of venous disease. Among the many advances include the elucidation of
an increasing role for matrix metalloproteinases as important mediators of the degenerative process involved with
venous insufficiency. This may be preceded by an inflammatory process which further contributes to venular
degeneration and endothelial dysfunction seen in advanced presentation of disease. Furthermore, genomic
analyses have shed light upon temporal expression patterns of matrix remodeling proteins in diseased tissue
samples. In this review we examine some of the current findings surrounding cellular, molecular and genetic
advances in delineating the etiology of chronic venous disease.
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A variety of mechanisms have been proposed as the eti-
ology of chronic venous insufficiency. One common hall-
mark of this disease is an elevated venous pressure [1-4].
Valve coaptation failure is an early inciting event; it is as-
sociated with venous wall distension, but the underlying
reason for this occurrence remains unexplained. Other
causes, such as perivascular fibrin cuffs, ischemia-hypoxia,
and growth factor trapping, have been proposed, and
there is evidence for white blood cell infiltration as a
marker for an inflammatory cascade [5]. The inflam-
matory cascade serves in life largely as a tissue repair
mechanism, and therefore this evidence poses the ques-
tion of what mechanism triggers the inflammation and
may sustain it [6-9].
Venous hypertension results in vein wall distension
and loss of the normal fluid shear stress [10-12]. These
changes in the biomechanical environment of veins facili-
tate a variety of cellular responses: they alter the transport
of inflammatory mediators (for example, accumulation of* Correspondence: gwss@bioeng.ucsd.edu
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The role of inflammation comes closely into focus to
understand the etiology of chronic venous insufficiency.Collagen/Elastin
Varicose veins are composed of tortuous and non-
tortuous segments [13]. The non-tortuous segments are
similar in structure to a healthy vein. These, however, are
interspersed with tortuous segments, which display alter-
ations in collagen and elastin content throughout the wall.
The tortuous segments have non-uniform structure with
alternating regions of hypertrophy and atrophy [13-15].
Atrophied regions have decreased extracellular matrix and
smooth muscle cells, while hypertrophied regions have
disruption of the smooth muscle cells with an increased
amount of extracellular matrix [15]. There is conflicting
data regarding collagen content in varicosities, although
most studies have demonstrated that it is increased com-
pared with healthy veins [13,14,16,17].
Xiao et al. demonstrated increased collagen synthesis
in smooth muscle cell cultures from varicose veins com-
pared with healthy controls [18]. There are multiple sub-
types of collagen, which have a variety of roles. Veins are
nonlinear viscoelastic structures. Type I collagen tendsLtd. This is an Open Access article distributed under the terms of the Creative
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properties of veins at higher levels of distension, while
Type III collagen provides also a stress at lower levels of
distension [19,20]. Multiple studies have demonstrated
an increase in Type I, and decrease in Type III, collagen
in similar cell cultures, as well as varicose vein tissue
[19-21]. Jeanneret et al. demonstrated that decreased
Type III collagen in varicose vein segments, as compared
with controls without known venous insufficiency, corre-
lated with increased distensibility with Valsalva [20]. Of
note, cell culture from dermal fibroblasts of patients
with varicosities demonstrated similar findings, suggest-
ing a systemic alteration in collagen synthesis [19].
Studies focusing on the layers of the vein wall reveal a
variety of alterations in chronic venous insufficiency. The
intima has a disrupted elastic lamina with alterations in
collagen content [20,22,23]. Smooth muscle cells within
the lamina are increased both in number and size [15].
Within the media, the smooth muscle cell bundles are dis-
rupted by increased content of collagen and elastin and de-
velopment of fibrosis, as demonstrated by histology, with
increased quantities of hydroxyproline, a collagen precur-
sor [16,19,24]. The disruption of the vein wall structure
goes hand in hand with dilatation of the vein wall in vari-
cosities, aided by the lack of contact with smooth muscle
cells and impairment of the contractile properties of the
vein tissue [16]. The adventitia has decreased elastin [20].
The amount of elastin appears to be inversely related to
the diameter of a vessel [20]. With age, there are decreased
levels of elastin synthesis, as evidenced by components
such as tropoelastin and lysyl oxidase-like 1 (LOXL-1)
[25]. However, in patients with varicosities, there is
an even greater decrease in LOXL-1 than in age-matched
controls [25]. Sansilvestri et al. demonstrated thickened
and fragmented elastic fibers not only in varicose vein seg-
ments but also in the skin of patients with chronic venous
insufficiency [17]. This evidence provides further support
for a potential systemic alteration in extracellular matrix
in individuals with venous insufficiency.
Extracellular matrix components/glycoproteins
There are a variety of other alterations in the extracellular
matrix in chronic venous insufficiency. Laminin, which
plays an important role in remodeling and extracellular
matrix organization, is increased in varicose vein tissue
[17]. In addition, in both varicose vein tissue and the skin
of the patients with varicose vein disease there is an in-
crease in fibrillin-1, a key structural component of elastic
fibers [17,26]. A 2005 study found increased transforming
growth factor-beta (TGF-β) in varicose vein tissue, com-
pared with control [13]. A significant difference was also
noted within the varicose tissue, with higher TGF-β in
areas of tortuousity [13]. A more recent study confirmed
this finding, and demonstrated an increase in active TGF-βin varicose vein tissue [27]. Interestingly, fibrillin 1 has re-
cently been shown to play a role in the limiting the activa-
tion of TGF-β [28].
Endothelial activation
Endothelial cells are exquisitely sensitive to their mech-
anical environment, for example, the degree of fluid
shear stress on their plasma membrane, the stretch due
to vessel distension, and the stiffness of the extracellular
matrix to which they are attached. Many of these factors
are altered in varicose veins and may thus influence the
behavior of endothelial cells. Multiple studies have dem-
onstrated endothelial activation in the veins of patients
with varicosities. This serves as a major contribution to the
proinflammatory state in chronic venous insufficiency. For
example, exposing endothelium to increased pressure re-
sults in enhanced synthesis of VCAM, ICAM, and ELAM.
In patients with varicose veins, ICAM, VCAM, laminin,
E-selectin, and ELAM are elevated in the tissue and in
serum in a soluble form [9,29-31].
Endothelial dysfunction
Carrasco et al. demonstrated impaired endothelial-dependent
relaxation in response to acetylcholine in varicose vein
segments [32] just as in diseased arteries. In addition,
unlike previous studies that demonstrated decreased con-
tractility to noradrenaline stimulation, this study also
found an increased response [32]. The authors proposed
that this may be a compensatory response to prolonged
distension of varicose veins.
Matrix metalloproteinases
Matrix metalloproteinases (MMPs) are involved in extra-
cellular matrix degradation and may thus play a central
role in the restructuring of veins in chronic venous insuffi-
ciency [14]. Multiple studies have confirmed increased
levels of tissue and plasma MMPs in chronic venous in-
sufficiency, including MMP-1, MMP-2, MMP-3, MMP-9,
and MMP-13 [17,18,33-35].
Gillespie et al. demonstrated an MMP-1 increase in
varicose vein segments, although to a lesser extent at the
distal aspect of the varicosity [33]. The same study dem-
onstrated significantly less MMP-13 protein levels at the
distal extent of a varicosity, as compared with the prox-
imal aspect [33].
MMP-2 and MMP-3 degrade elastin and collagen,
abnormalities frequently identified in venous disease
[17,18]. Smooth muscle cells cultured from varicose veins
have increased MMP-2 compared with healthy con-
trols [18]. Sansilvestri-Morel et al. demonstrated in-
creased MMP-1, MMP-2, and MMP-3 in both varicose
vein tissue and the skin of patients affected with chronic
venous disease [17].
Figure 1 Micrograph of post-capillary venule upstream of
occlusion point. Arrows point to the release of active MMP-8 from
accumulating adherent and rolling leukocytes (leukocyte-fluorescence
co-localization). V = venule; A = arteriole. Length bar = 100 μm.
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ation of the inferior vena cava in response to MMP-2
[35]. These investigators propose that this relaxation
could be related to smooth muscle cell hyperpolarization
secondary to a calcium-dependent potassium channel
BKCa [35]. In a follow-up study of rat chronic venous in-
sufficiency segments exposed to increased tension, the
same group demonstrated increased MMP-2 and MMP-
9, and reduced contractility of the vein segment [34].
They propose this as a potential mechanism for the ven-
ous dilatation seen in chronic venous disease.
There is a conflicting record regarding MMP-2, with
several studies demonstrating decreased levels of this en-
zyme in varicose vein tissue [14,36]. This could result in
extracellular matrix accumulation, and in possibly con-
tribution to the alternating regions of hypertrophy and
atrophy in varicosities [14]. In addition, both groups that
identified decreased levels of MMP-2 also demonstrated
increased levels of tissue inhibitors of metalloproteinese
(TIMP-1).
There have been recent efforts to detail the early versus
late MMP expression patterns in venous disease. Alsaigh
et al. examined MMP activity in vivo over an acute
90-minute occlusion and reperfusion of postcapillary ve-
nules in the rodent mesentery. Utilizing microzymographic
techniques, this group determined that accompanying a
short rise in local blood pressure together with a reduction
of the fluid shear stress, there is early expression of active
MMP-1, MMP-8, and MMP-9, with MMP-1 and MMP-9
being released from endothelial cells and MMP-8 being
released from rolling and adherent leukocytes (Figure 1).
There was also an increased presence of TIMP-1 and
TIMP-2, again suggesting an important interplay between
MMPs and their inhibitors in the early stages of venous
occlusion. The relatively early expression of MMPs (within
minutes) detected in this study suggests that the degrada-
tive activity of these proteases may be early culprits that
initiate the inflammatory reactions responsible for the
breakdown and restructuring of the venous wall seen in
venous disease [37].
Depending on the particular MMP involved, the MMP
activity may not only be associated with breakdown of
extracellular matrix proteins but also cleavage of membrane
receptors, such as vascular endothelial growth factor-2
(VEGFR-2) [37]. Such receptor cleavage may compromise
endothelial viability.
Cytokines
Typical for all inflammatory states, a shift in cytokine
expression pattern is encountered in varicose vein tissue.
These cytokines serve for the most part the repair side
of inflammation and are synthesized by intact cells that
involve endothelium, macrophages, smooth muscle cells,
and others. TGF-β1 has a variety of roles, including akey role in vascular remodeling [27]. It recruits macro-
phages and fibroblasts and inhibits expression of MMP-1
[10,38]. In addition, in the presence of other growth
factors, TGF-β1 inhibits collagenase synthesis and syn-
ergistically increases TIMP expression [39]. TGF-β1 is
increased in varicose veins compared with normal tis-
sue [13,27]. This difference has been further broken
down to demonstrate increased TGF-β1 in the tortu-
ous segments of varicose veins, as compared with non-
tortuous segments [13].
Isoform nitric oxide synthase iNOS is present only at
low levels in normal non-injured tissue. However, in vari-
cose vein tissue, it is significantly elevated [13]. Similar to
the distribution pattern of TGF-β1, iNOS is present in
greater amounts at the tortuous segments of varicosities,
compared with non-tortuous segments [13].
In addition, Shoab et al. demonstrated increased vas-
cular endothelial growth factor (VEGF) in patients with
chronic venous disease [40].
Leukocytes
Already during early stages of inflammation, leukocytes
roll along the endothelium utilizing the cellular adhesion
molecule L-selectin. Once stimulated, leukocytes shed
this molecule and express integrins to facilitate extrava-
sation into the tissue [12]. A variety of studies have dem-
onstrated increased degranulation and extravasation of
leukocytes in patients with venous hypertension.
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monocyte L-selectin as detected with flow cytometry in
patients with chronic venous insufficiency with venous
hypertension [41]. Interestingly, in a follow-up study in
2000 by Junger et al., no shift in expression of L-selectin
on neutrophils or monocytes was demonstrated in healthy
controls compared with patients with chronic venous in-
sufficiency following experimental venous hypertension
[42]. The study by Junger demonstrated a decreased ex-
pression of L-selectin in lymphocytes, however [42].
Lymphocytes
T-lymphocytes have also been shown to be at least par-
tially involved in the inflammatory process seen in ven-
ous disease. By analyzing blood obtained from varicose
veins of patients with CVD, Ojdana et al. were able to
show that levels of CD4+ T lymphocytes measured from
varicosities was significantly elevated compared to over-
all measured levels of CD4+ cells. The increased level of
these cells, as well as other T-cell subpopulations mea-
sured by this group, indicate that T-cells may also be par-
tially involved in the pathogenesis of CVD [43].
Mast cells
Mast cells can carry out a wide variety of functions that
mediate the inflammatory cascade by mediators derived
from their granules on endocytosis. Pascual et al. dem-
onstrated a significantly elevated infiltration of mast cells
into varicose vein walls, as opposed to healthy controls
[27]. Mast cell chymase is an activator of MMP-1 (a pro-
collagenase) and MMP-3 [27,44], and also stimulates the
release of TGF-β, which plays an integral role in vascular
remodeling [27]. Mast cells also secrete tryptase, which
can degrade elastin, Type IV collagen, proteoglycans, and
fibronectin [27].
Smooth muscle cells
Smooth muscle cells contribute distinctly to many aspects
of the elasticity of a vein. Varicose veins have decreased
layers of smooth muscle cells in the subintima of the wall,
as well as a disrupted and disorganized smooth muscle
structure within the media [13,24]. But the decreased
quantity of smooth muscle cells is accompanied by an in-
creased cell size [13]. An interesting study by Knappen
et al. supports the finding of increased smooth muscle cell
volume, correlated with an increased estrogen receptor-β
expression [45].
The smooth muscle cells within varicosities have dem-
onstrated altered function, as well as size. Metcalfe et al.
found that smooth muscle cells of varicose vein have de-
creased contractility compared with controls [15]. This
was linked to a decrease in the purinergic P2X1 receptor,
an adenosine triphosphate-gated cation channel [15]. The
investigators demonstrated a transition from contractile tosynthetic function of smooth muscle cells, as evidenced by
increased intracellular organelles, as well as upregulated
purinergic receptor subtypes P2Y1 and P2Y2 [15]. A sub-
sequent study by Xiao et al. demonstrated significantly de-
creased levels of alpha-smooth muscle actin, smooth
muscle myosin heavy chain, and smoothelin, components
integral for the contractile function of the smooth muscle
cell [18].
Valves
Valve destruction and valve coaptation failure are key
contributors to venous insufficiency and hypertension
[46]. Angioscopic evaluation shows a decreased number of
valves in the great saphenous vein in patients with chronic
venous insufficiency [46].
In addition to a decrease in valve number in chronic
venous insufficiency, the structure of the valve is affected
as well. Increased pressure at the valve, as well as de-
creased shear stress, can trigger an inflammatory cascade,
with subsequent valve damage and remodeling [47]. A
study of patients undergoing surgery for chronic venous
insufficiency found infiltration of valve leaflets and the
vein wall by monocytes and macrophages [48]. These
tissues also demonstrated destruction of collagen and
disruption of the elastic lamina, with redistribution of
elastic fibers throughout the vein wall.
Lymphatics
Recent studies have also examined the specific genes in-
volved in venous valve morphogenesis [49]. A report by
Bazigou et al. makes the important discovery that developing
venous valves expressed, among other proteins, prospero-
related homeobox1 (Prox1), VEGFR3, and integrin-a9, all
previously characterized as important regulators of lym-
phangiogenesis [50,51]. This group further suggests that
the development of these two cell types (venous endo-
thelial and lymphatic endothelial) may display plasticity
upon normal development; the molecular switches con-
trolling lymphatic development may also control ven-
ous valve development, and these switches may be
controlled, in turn, by contextual environmental cues
such as blood flow and shear stress. These observations
shine a bright light on congenital vascular anomalies
such as Klippel Trenaunay Syndrome, a malformation
characterized by improper vascular and lymphatic de-
velopment and soft tissue hypertrophy [52]. Further
investigation should be encouraged in order to exam-
ine the interrelated nature of pathological lymphatic and
venous development.
Genetics
A genetic component of chronic venous insufficiency
has only recently begun to be identified. Recent areas
of study have focused on connexins, alterations in
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box protein C2 (FOXC2), hyperhomocysteinemia, and
Type-I plasminogen activator inhibitor polymorphisms.
Connexins comprise a large family of gap junction pro-
teins found to be important in a variety of developmental
and physiological processes. Connexin-37 (Cx37) was pre-
viously shown to be highly expressed on blood vessel
endothelium [53], and recent genetic and molecular ana-
lyses have shown that Cx37 is important for proper ven-
ous valve development [54]. In their study, Munger et al.
demonstrated that venous valves are completely absent
in Cx37-/- mice. Additionally, this group also identified
two other connexins (Cx43 and Cx47) that are expressed
in venous endothelium in a defined spatial fashion,
suggesting that proper localized expression patterns of
connexins may be important for proper development of
venous vasculature.
Thrombomodulin (TM) downregulates the coagulation
cascade by complexing with thrombin and activating
Protein C. Le Flem et al. investigated the role of throm-
bomodulin gene mutations as a potential etiology for
venous thromboembolism. Knowing that thrombomodulin
can also have a role in proliferation, they also investigatedFigure 2 Schematic representation of the interplay of factors involveda potential link for thrombomodulin genetic mutations
in patients with varicose veins. Three thrombomodu-
lin DNA mutations were evaluated in patients who
had participated in the Paris Thrombosis Study, a French
case–control study of venous thrombosis. A-1208/-1209
TT deletion was increased to a statistically significant
level in patients with varicosities [55]. In addition,
this mutation was in linkage disequilibrium with +1418
C/T substitution (Ala 455 Val substitution) in sixth epi-
dermal growth factor-like TM module. This mutation
has an effect on the proliferative function of throm-
bomodulin [55].
The increased genomic expression of several extracellu-
lar matrix-remodeling proteins was evaluated in a study
by Cario-Toumaniantz et al. Among the genes investi-
gated, increased mRNA expression of MGP was found
to be significantly increased in varicose compared with
nonvaricose veins. Importantly, the mRNA-to-protein turn-
over was also investigated, and the authors confirm via
Western blotting the elevated levels of MGP in varicose
veins. These veins had increased smooth muscle cell prolif-
eration and increased extracellular matrix mineralization,
which can be attenuated by warfarin (an MGP inhibitor)in the pathogenesis of venous insufficiency.
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man saphenous smooth muscle cells [56].
MGP has a role as an inhibitor of matrix calcification.
Utilizing gene knockdown techniques, Cario-Toumaniantz
et al. were able to demonstrate an increase in mineralization
of both varicose and non-varicose smooth muscle cell
cultures corresponding to decreased levels of MGP.
Microarray analysis also demonstrated alterations in
cell organization genes such as actin—which could con-
tribute to the known structural and contractile alterations
seen in the varicose vein wall—in addition to an increase
in TIMP-1. The shifting balance between TIMPs and
MMPs in varicose vein tissues may affect the ability of
proteolytic enzymes to degrade components of the extra-
cellular matrix, thereby contributing to the restructuring
of the vein wall [56].
The study by Cario-Toumaniantz et al. also demon-
strates alteration in gene expression of dermatopontin
and tenascin C within the varicose vein but is not repli-
cated in smooth muscle cell culture. Dermatopontin in-
teracts with decorin to regulate collagen fibrillogenesis,
while tenascin C induces MMPs and modulates cell-
matrix attachment [56].
Mellor et al. illuminated a specific genetic defect in
the FOXC2 gene that they found to be associated with
venous valve failure and reflux. FOXC2 encodes a regula-
tory transcription factor and is involved in lymphatic
and vascular development [57]. The authors investigated
the hypothesis that individuals with mutations (frame-shift
or deletion) in the FOXC2 gene present with a greater level
of venous reflux in lower limbs. By utilizing venous duplex
ultrasound, they found that all 18 patients examined that
possessed a FOXC2 mutation displayed pathological ven-
ous reflux. Additionally, patients with lymphatic distichia-
sis syndrome were also found to have a mutation in this
gene with subsequent lymph reflux. Therefore, this study
brings to light an important link between genetics and the
pathophysiology of primary venous insufficiency, with the
suggestion that FOXC2 is an important gene involved with
normal venous and lymphatic valve development [57].
Sam et al., investigated the correlation between hyper-
homocysteinemia (HHcy) and chronic venous insuffi-
ciency. The investigators found a statistically significant
increase in HHcy in patients with venous insufficiency
(CEAP 2–6) compared with the accepted prevalence in
population (39% vs. 5%). An increase in the severity of ven-
ous disease resulted in an increased likelihood of elevated
HHcy levels. The most common genetic mutation for
HHcy is methylene tetrahydrafolate reductase (MTHFR)
C677T polymorphism. Fifteen percent of patients in the
study were homozygous for this mutation, compared with
5% in a healthy population [58].
Type I plasminogen activator inhibitor (PAI-1) is a regu-
lator of the fibrinolytic system, and variations in plasmalevels of PAI-1 can disrupt the clearance of fibrin. The
PAI-1 4G/5G gene polymorphism consists of a deletion or
addition of a guanosine in the promoter region of the
PAI-1 gene [59]. This polymorphism and its association
with chronic venous insufficiency was investigated by
Katrancioglu et al. In their examination of 34 patients
who present with chronic venous insufficiency, the PAI-1
4G allele was found to be increasingly present compared
with normal control patients. Additionally, the 4G allele
was associated with a 3.25-fold increase in risk for devel-
opment of chronic venous insufficiency [60].
Summary
There is increasing evidence to support the notion that
among several possible trigger mechanisms, chronic
venous insufficiency is to a considerable degree a blood
pressure–driven inflammatory disease. Elevated venous
pressure and a shift in fluid shear stress generate an ab-
normal biomechanical environment in venules, in their
walls and in valves, which may initiate early activation of
degrading enzyme activity and in turn set in motion an
inflammatory cascade (Figure 2). A variety of pro- and
anti-inflammatory biomarkers can be detected of which
no particular one is specific for chronic venous insuffi-
ciency. It is possible that a variety of genetic polymor-
phisms increase the susceptibility to changes mechanical
environment and serve as risk factor for chronic venous
insufficiency.
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